Amid fierce rivalries over the latest generation of cancer treatments , drugmakers have been weaving a complex web of collaborations on combination therapies spanning much of the pharmaceutical industry. As the true significance for patients of molecules that recruit or rescue immune functions to destroy tumours is becoming clear, their developers continue to seek ideal partner drugs .